01Assess
Cause first
Sudden, patchy or unexplained loss is assessed before long-term medication is considered.
Medical Treatment · Hair Loss
Diagnosis before medicine · formulation before dose
Medical Treatment for Hair Loss
Minoxidil, finasteride and dutasteride have different roles and safety considerations. Selection begins with the diagnosis, life stage, health history, exact formulation and a plan that can be reviewed over time.
Photographs can document a pattern. They do not replace examination, medicine reconciliation, product information or review of cardiovascular, reproductive and mental-health considerations.
Purpose and Scope
Four possible roles
Medication is a long-term treatment route, not a shortcut around diagnosis.
Ingredient, formulation, authorisation, individual risks and monitoring remain separate parts of the decision.
02Select
Match form and person
Topical and oral routes differ in exposure, contraindications and monitoring.
03Monitor
Make benefit reviewable
Standardised photographs, clinical findings and tolerability are documented separately.
04Reconsider
Continuation is not automatic
Side effects, life plans, new findings or limited benefit may lead to pause, change or stopping.
Medical Assessment
From pattern to a personal decision
Five levels come before a medication recommendation.
A personal decision requires a diagnosis, examination, a complete medicine list and the current information for the actual product.
- 01
History and course
Onset, pace, family history, health conditions and previous treatments are reviewed.
- 02
Pattern and scalp
Miniaturisation, inflammation, scarring, breakage and distribution are assessed.
- 03
Life stage and reproduction
Sex, pregnancy, breastfeeding and reproductive plans can change medicine selection.
- 04
Risks and interactions
Cardiovascular history, mood, sexual function and all medicines or supplements are considered.
- 05
Baseline and aim
A realistic timescale and criteria for continuing, changing or stopping are agreed.
Medicines in Context
Two medicine families
Ingredient, formulation and authorisation must remain visible.
The same ingredient can have a different role and risk profile according to route, product and person.
01Growth modulation · multiple forms
Minoxidil
Topical products and any proposed oral off-label use require separate consideration because exposure, risks and monitoring differ.
Decision boundaryProduct, formulation, scalp condition and cardiovascular history must remain visible.
Open Minoxidil025-alpha-reductase inhibitors
Finasteride and Dutasteride
The two medicines are distinguished by indication, formulation, duration in the body and safety information.
Decision boundaryDutasteride is not presented as an automatically better next step; authorisation and personal risk matter.
Open Finasteride and DutasterideAuthorisation and Use
Product-specific, country-specific
Four questions keep authorisation, formulation and medical use distinct.
An ingredient name alone does not show whether a particular product is authorised for hair loss in a given country.
Which diagnosis?
An indication for androgenetic alopecia is not transferred to every form of diffuse or inflammatory loss.
Which formulation?
Solution, foam, spray and tablet can have different exposure and safety considerations.
Which country and product?
Available products, indications and supply rules vary by market.
On-label or off-label?
Any departure from the authorised use is identified and discussed before a decision.
Personal Treatment Plan
Prescription is not automatic
The outcome is a reviewable long-term plan, not automatically a prescription.
The decision considers diagnosis, product status, benefit-risk balance, daily practicality and reliable follow-up.
One formulation
A clearly reasoned topical or oral route with a defined role and baseline.
Ordered combination
More than one measure only when roles, interactions and evaluation remain distinct.
Another priority
Further diagnosis, scalp treatment, observation or a separate surgical assessment may come first.
No medication
An unfavourable benefit-risk balance or personal preference can make no medicine the right outcome.
Monitoring
Baseline · tolerability · course · review
Effect, tolerability and life circumstances are reviewed separately.
Hair-cycle change is slow, while adverse effects may appear earlier, so review points have different purposes.
- 01Start
Record the baseline
Findings, photographs, current medicines and the precise product are documented.
- 02Early
Review tolerability
Scalp, cardiovascular, sexual and mood-related symptoms are considered in context.
- 03Course
Assess the hair cycle
Comparable photographs and clinical findings are interpreted over an appropriate period.
- 04Long term
Decide again
Benefit, burden, new health information and alternatives guide continuation.
Safety and Alternatives
Benefit-risk balance over time
Treatment continues only while benefit, safety and personal circumstances remain aligned.
Local reactions, systemic symptoms, sexual function, mood, reproductive considerations and interactions require product-specific discussion.
01Form-specific
Separate local and systemic effects
Scalp irritation differs from cardiovascular, sexual or mood-related symptoms.
02Person-specific
Consider life stage
Pregnancy, reproductive plans, cardiovascular risks and other medicines may change the plan.
03Alternatives
Change or stop when needed
Further assessment, observation, another medicine or surgical review may be more appropriate.
New or severe symptoms require timely medical review. Current product information and local medical advice take priority over general website information.
The Doctor Aslan Approach
Medical position
A medicine becomes meaningful only when its formulation, purpose and limits can be explained.
Medical responsibility includes disclosing authorisation, off-label use, practical burden and individual risk — and stopping a plan that no longer remains sound.
Diagnosis before prescription
Visible loss is medically assessed before a medicine is selected.
Formulation before dose
Topical and oral routes receive separate safety and monitoring plans.
Explanation before off-label use
A use outside authorisation is identified and documented.
Review before continuation
Benefit and burden are reconsidered at planned points.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information; no personal prescription
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Medical Treatment for Hair Loss?+
Medical Treatment for Hair Loss is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Medical Treatment for Hair Loss?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Physician-led · no product or outcome promise